Market Brief

The articles are produced in Chinese only.

Author

馮兆山先生(Michael Fung)
經理

現任職輝立經理,對投資股票、期權經驗豐富。本人樂意為客戶提供投資分析及買賣策略。歡迎各位來電交流心得。
Phone:
22776655

中國生物製藥 (1177.HK) – 中長線行業前景秀麗

Thursday, November 15, 2018 Views4464


 

  • 中國生物製藥(1177)早前獲納入為恆生指數成份股,充分反映其規模, 業績等具有一定水平.

  • 目前, 集團的產品種類涵蓋多個範疇,包括腫瘤、肝病、心腦血管病和鎮痛劑等的治療範圍。

  • 近年, 集團積極加大研發的投放, 今年上半年的研發開支共13.28億元人民幣, 佔集團收入約13.7%.

  • 今年上半年, 集團剛獲得多項生產批件, 包括:醋酸加尼瑞克注射液、鹽酸安羅替尼膠囊3個規格、注射用左亞藥酸鈣等;同期並獲得14項臨床批件項目, 及3件新申報臨床項目.

  • 與此同時, 集團附屬公司正大天晴藥業集團就其研發的逹比加群酯膠囊 (該新產品為口服型抗凝血藥, 標準規格為75mg及100mg), 並已獲得中國國家食品藥品監督管理總局藥品評審中心受理及批准.

  • 業績方面:今年上半年,集團收入97.25億元人民幣,按年增加三成,純利升24.1%至13.66億元人民幣;若計入權益投資及金融資產之未實現公允價值利潤及虧損和海外匯兌差異淨額前,盈利則升41.9%至14.27億元人民幣。

  • 新產品銷售佔集團總收入約14.5%。

  • 至今年6月底,集團之現金及銀行結餘約55.4億元人民幣,資產及負債比率約30.6%。

  • 看圖睇勢, 中國生物製藥於2018年11月13日以陽燭收市, 收市價為8.08元;另外, 目前10天線 (HK$7.901) 剛升穿50天線 (HK$7.58), 短期走勢轉強可期, 可候低吸納.

  • 以2018年11月1日的上升裂口底部為第一注買入位 = HK$7.55;若股價進一步突破2018年11月8日的高位 = HK$8.43, 可追入第二注. 止蝕價定於20天線的HK$7.3

     

    本人馮兆山為證監會持牌人士。截至本評論文章發表日止,本人及/或其有聯繫者並無持有全部提及之證券的所有相關財務權益.

     

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
E-Check
Login
Investor Notes
Free Subscribe
Contact Us